Universidade Federal de São Paulo - UNIFESP.
Universidade de São Caetano do Sul - USCS.
Acta Reumatol Port. 2021 Apr-Jun;46(2):120-125.
many Juvenile Idiopathic Arthritis (JIA) patients reach inactivity while medicated, but there are no guidelines to determine the moment or method for discontinuing medications. We present the flare rates and remission and possible influencing factors after therapy discontinuation in children with JIA.
data was collected from charts of JIA patients (n=70) in remission on medication, who had their drugs withdrawn.
Seventy patients fulfilled inclusion criteria and were included for analysis. The mean time of inactive disease on medication until tapering or withdrawal was 15.6±6.7 months; 45 (64.3%) patients remained in remission and 25 (35.7%) flared. There was no difference between groups regarding sex, age, JIA subtype, disease duration, time in remission on medication and scheme of therapy withdrawal. Patients who fulfilled Wallace criteria for remission off medication had lower flare rates than those who did not achieve 12 months of remission after the medication withdrawal (p<0.0001). Patients who used biologic DMARDs plus synthetic DMARDs appeared to flare more (77.8% vs 29.5% respectively, p=0.008) and presented shorter periods of inactivity off medication (15.3±24.7 vs 32.3 ± 31.7 months respectively, p=0.049) compared to those who used only synthetic DMARDs.
It is possible that gradual drug tapering is not necessary for JIA patients, but caution must be exerted in those patients using biologic DMARDs, weighing carefully the decision to withdraw medication, due to their higher flare rates and shorter times of inactive disease after the medication withdrawal.
许多幼年特发性关节炎(JIA)患者在接受药物治疗时达到无活动期,但目前尚无确定停止药物治疗的时机或方法的指南。我们报告了 JIA 患儿停药后出现的复发率、缓解率和可能的影响因素。
从正在接受药物治疗、处于缓解期的 JIA 患儿(n=70)的病历中收集数据,这些患儿的药物已被停用。
70 名患者符合纳入标准并被纳入分析。在药物治疗期间达到无疾病活动期直至逐渐减少或停药的平均时间为 15.6±6.7 个月;45(64.3%)名患者仍处于缓解期,25(35.7%)名患者复发。在性别、年龄、JIA 亚型、疾病持续时间、药物治疗缓解时间和停药方案方面,两组之间没有差异。符合停药时无药物缓解标准的患者复发率低于停药后 12 个月未达到缓解的患者(p<0.0001)。使用生物 DMARDs 联合合成 DMARDs 的患者似乎更容易复发(分别为 77.8%和 29.5%,p=0.008),停药后无疾病活动期的时间更短(分别为 15.3±24.7 个月和 32.3 ± 31.7 个月,p=0.049),与仅使用合成 DMARDs 的患者相比。
对于 JIA 患者,逐渐减少药物剂量可能不是必需的,但对于使用生物 DMARDs 的患者,必须谨慎,仔细权衡停药的决定,因为他们的复发率更高,停药后无疾病活动期的时间更短。